{"name":"USWM","slug":"uswm","ticker":"","exchange":"","domain":"uswm.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1979-01-01","label":"Corgard first approved","drug":"Corgard","drugSlug":"nadolol","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Open Label Lofexidine HCL","genericName":"Open Label Lofexidine HCL","slug":"open-label-lofexidine-hcl","indication":"Opioid withdrawal syndrome","status":"phase_3"},{"name":"lofexidine HCl","genericName":"lofexidine HCl","slug":"lofexidine-hcl","indication":"Opioid withdrawal","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ADP adoptive cell therapy","genericName":"ADP adoptive cell therapy","slug":"adp-adoptive-cell-therapy","indication":"Other","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Corgard","genericName":"NADOLOL","slug":"nadolol","indication":"Angina pectoris","status":"marketed"}]}],"pipeline":[{"name":"ADP adoptive cell therapy","genericName":"ADP adoptive cell therapy","slug":"adp-adoptive-cell-therapy","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Corgard","genericName":"NADOLOL","slug":"nadolol","phase":"marketed","mechanism":"Beta-2 adrenergic receptor","indications":["Angina pectoris","Hypertensive disorder"],"catalyst":""},{"name":"Open Label Lofexidine HCL","genericName":"Open Label Lofexidine HCL","slug":"open-label-lofexidine-hcl","phase":"phase_3","mechanism":"Lofexidine is an alpha-2 adrenergic agonist that reduces noradrenergic hyperactivity associated with opioid withdrawal.","indications":["Opioid withdrawal syndrome"],"catalyst":""},{"name":"lofexidine HCl","genericName":"lofexidine HCl","slug":"lofexidine-hcl","phase":"marketed","mechanism":"Lofexidine is an alpha-2 adrenergic agonist that reduces noradrenergic hyperactivity in the central nervous system to alleviate opioid withdrawal symptoms.","indications":["Opioid withdrawal"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":1,"marketed":2,"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}